Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of SPT-300 GlyphAllo, a prodrug of allopregnanolone, in adults aged 18 to 65 years with major depressive disorder MDD, including those with or without anxious distress. This Phase 2 randomized, double-blind, placebo-controlled study aims to better understand how SPT-300 impacts depressive symptoms compared to placebo. Participants will be randomly assigned to receive either SPT-300 capsules or a matching placebo once daily for 42 days. The study is designed as a parallel-group trial with two arms one receiving the experimental drug SPT-300 and the other receiving placebo. Treatment effects will be closely monitored during this 6-week period. Throughout the study, participants will undergo assessments including the Hamilton Depression Rating Scale-17 HAM-D-17 and the Clinical Global Impression - Severity CGI-S to measure changes in depressive symptoms from baseline to day 42. Safety and tolerability will also be evaluated. The total participation duration extends until study completion in March 2027, with regular visits to monitor progress and well-being.
Actively Recruiting
Anterior Cruciate Ligament ACL Degeneratio Mucosa is a condition caused by mucoid degeneration of the ACL, leading to impaired daily function. The exact cause of this condition is unknown. Researchers are studying a surgical technique called ACL decompression, which involves making longitudinal incisions and removing extrafibrous mucoid tissue to address this problem. The study focuses on patients with ACL Degeneratio Mucosa who have decided to undergo surgical treatment. This treatment involves the decompression procedure applied to the affected ligament. The study does not mention comparison groups or placebos, as it is observational in nature. Participants will be followed for up to 24 months, during which their knee function will be closely monitored. Assessments include measuring range of motion, knee stability in different directions, and functional scores using the International Knee Documentation Committee Questionnaire IKDC and the Knee Injury and Osteoarthritis Outcome Score KOOS. These evaluations occur at 12 and 24 months after treatment to track recovery and knee performance.
Actively Recruiting
Researchers are evaluating the outcomes of Double-bundle Posterior Cruciate Ligament Reconstruction DB-PCLR for patients with Posterior Cruciate Ligament PCL tears. This observational study aims to assess whether DB-PCLR, which reconstructs both the anterolateral and posteromedial bundles of the PCL, can improve patient results compared to the single-bundle procedure. The study is led by Konrad Malinowski MD and focuses on patients with grade III symptomatic posterior instability. Participants will undergo the DB-PCLR procedure, which involves reconstructing both PCL bundles. The study monitors patients treated with this method to evaluate knee stability and function over time. There are no comparison groups, as this is an observational assessment of patients receiving DB-PCLR. During the study, participants will be followed up at 12 and 24 months after surgery. Researchers will assess knee posterior translatory stability using clinical tests such as the posterior sag, drawer, Lachman tests, and stress X-rays, as well as knee internal rotation stability. Functional outcomes will be measured using questionnaires like the International Knee Documentation Committee IKDC and the Knee injury and Osteoarthritis Outcome Score KOOS. Additionally, retear rates and range of motion ROM will be evaluated. The study will provide detailed follow-up on knee function and stability for up to two years post-treatment.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of the drug NBI-1065845 when used alongside other treatments for adults with Major Depressive Disorder MDD. This Phase 3 trial focuses on participants who have moderate to severe recurrent MDD or persistent depressive disorder, particularly those who have not responded well to oral antidepressants in their current depressive episode. Participants will take NBI-1065845 tablets orally once a day as an additional treatment. The study is open-label and single group, meaning all participants receive the same treatment. The trial will observe participants over the course of one year while they take the medication. During the study, participants will undergo assessments to monitor any treatment-emergent adverse events from the start through week 52. Researchers will evaluate how well participants tolerate the medication and ensure their safety throughout the treatment period. The total participation duration corresponds to the one-year treatment and monitoring phase.
Actively Recruiting
Lateral patellar dislocation often results in injury to the medial patellofemoral ligament MPFL, leading to ongoing instability of the knee. Researchers are evaluating the outcomes of reconstructing the MPFL using a fascia lata allograft with isometry assessment, combined with the Elmslie-Trillat tibial tuberosity osteotomy procedure. This study aims to assess how well this combined surgical approach improves knee stability and function in affected patients. Participants will undergo the MPFL reconstruction with fascia lata allograft, guided by isometry assessment, along with the Elmslie-Trillat tibial tuberosity osteotomy. Any additional patellofemoral lesions found during surgery will also be managed. This is a procedural study focused on this combined surgical treatment without a comparison group. During the study, participants will be monitored at 12 and 24 months after surgery. Researchers will evaluate lateral patella stability using apprehension and lateral luxation tests at both time points. Functional assessments include the International Knee Documentation Committee Questionnaire and the Knee injury and Osteoarthritis Outcome Score, as well as range of motion measurements. These evaluations will help measure the success of the surgery and patient recovery over two years.
Actively Recruiting
This research aims to assess the outcomes of treating Posteromedial Tibiofemoral Incongruence PMTFI, a condition where decreased curvature in the femoral metaphysis near the medial femoral condyle causes compression of the posterior horn of the medial meniscus PHMM during full knee flexion. This can lead to pain, snapping, discomfort, and worsening meniscus degeneration over time, especially during deep knee bending. The study evaluates a published arthroscopic technique designed to correct this incongruence with minimal necessary intervention, confirming the need for repair during surgery. The study involves a single treatment group receiving the PMTFI treatment following the specific published arthroscopic method. This surgical procedure aims to correct the anatomical incongruence that causes PHMM compression, potentially improving symptoms when conservative treatments have failed. There is no placebo or alternate comparison group mentioned. Participants will be monitored for up to 24 months after treatment. Researchers will assess pain presence during full knee flexion at 12 and 24 months, along with functional outcomes using the International Knee Documentation Committee Questionnaire IKDC and the Knee injury and Osteoarthritis Outcome Score KOOS at the same intervals. The study includes clinical evaluations, imaging confirmation, and arthroscopic assessment, focusing on symptom relief and functional improvement over time.